Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2014 | Research

Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer

Authors: Hao Zhang, Yuan Ren, Deyan Pang, Caigang Liu

Published in: World Journal of Surgical Oncology | Issue 1/2014

Abstract

Background

We investigated the expression status of AGBL2 and its inhibitor latexin in breast cancer stem cells and its clinical implications in order to lay a foundation for managing breast cancer.

Methods

CD44+/CD24- tumor cells (CSC) from clinical specimens were sorted using flow cytometry. AGBL2 expression status was detected in CSC and 126 breast cancer specimens by western blot and immunohistochemistry staining. The relationship between the AGBL2 protein and clinicopathological parameters and prognosis was subsequently determined.

Result

As a result, CSC are more likely to generate new tumors in mice and cell microspheres that are deficient in non-obese diabetic/severe combined immunodeficiency mice (NOD/SCID) compared to the control group. The AGBL2 protein was expressed higher in CSC induced to epithelial to mesenchymal transition (EMT) when compared to the control cells, and was found to be related to CSC chemotherapy resistance. After Spearman regression correlation analysis, AGBL2 was observed to be related to clinical stage, histological stage, and lymph node metastasis. In the Cox regression test, the AGBL2 protein was detected as an independent prognostic factor. Through immunoprecipitation, AGBL2 and latexin could form immune complexes.

Conclusions

These results demonstrate that AGBL2 is a latexin- interacting protein that regulates the tubulin tyrosination cycle and is a potential target for intervention.

Available only for authorised users

Gaffan J, Dacre J, Jones A: Educating undergraduate medical students about oncology: a literature review. J Clin Oncol. 2006, 24: 1932-1939. 10.1200/JCO.2005.02.6617.CrossRefPubMed

Dowling EC, Klabunde C, Patnick J: Ballard-Barbash R, for the International Cancer Screening Network (ICSN): Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen. 2010, 17: 139-146. 10.1258/jms.2010.010033.CrossRefPubMed

Dilaveri CA, Mac Bride MB, Sandhu NP, Neal L, Ghosh K, Wahner-Roedler DL: Breast manifestations of systemic diseases. Int J Womens Health. 2012, 4: 35-43.PubMedCentralCrossRefPubMed

Magee JA, Piskounova E, Morrison SJ: Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012, 21: 283-296. 10.1016/j.ccr.2012.03.003.PubMedCentralCrossRefPubMed

Wang J, Cao MG, You CZ, Wang CL, Liu SL, Kai C, Dou J: A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. Cell Mol Biol (Noisy-le-grand). 2012, 58: OL1641-OL1645.

Sahab ZJ, Hall MD, You Me S, Sivanesan D, Yun J, Deepak K, Byers SW: Tumor suppressor RARRES1 interacts with cytoplasmic carboxypeptidase AGBL2 to regulate the α-tubulin tyrosination cycle. Cancer Res. 2011, 71: 1219-1228. 10.1158/0008-5472.CAN-10-2294.PubMedCentralCrossRefPubMed

Arimatsu Y: Latexin: a molecular marker for regional specification in the neocortex. Neurosci Res. 1994, 20: 131-135. 10.1016/0168-0102(94)90030-2.CrossRefPubMed

Hatanaka Y, Uratani Y, Takiguchi-Hayashi K, Omori A, Sato K, Miyamoto M, Arimatsu Y: Intracortical regionality represented by specific transcription for a novel protein, latexin. Eur J Neurosci. 1994, 6: 973-982. 10.1111/j.1460-9568.1994.tb00592.x.CrossRefPubMed

Normant E, Gros C, Schwartz JC: Carboxypeptidase A isoforms produced by distinct genes or alternative splicing in brain and other extrapancreatic tissues. J Biol Chem. 1995, 270: 20543-20549. 10.1074/jbc.270.35.20543.CrossRefPubMed

10.

Normant E, Martres MP, Schwartz JC, Gros C: Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor. Proc Natl Acad Sci U S A. 1995, 92: 12225-12229. 10.1073/pnas.92.26.12225.PubMedCentralCrossRefPubMed

11.

Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF: The prognostic role of a gene signature from tumorigenic breast cancer cells. N Engl J Med. 2007, 356: 217-226. 10.1056/NEJMoa063994.CrossRefPubMed

12.

Ke Y, Xu GW, Hagiwara K, Zhang JM, Ning T, Wang B, Su XL, Feng LY, Lu GR, Lu YY, Harris CC: Isolation and sequencing of the target genes induced by chemical carcinogen. Science in China (Series C). 1996, 26: 85-91.

Title: Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer
Authors: Hao Zhang
Yuan Ren
Deyan Pang
Caigang Liu
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-12-142

At a glance: The STEP trials

Springer Medicine

Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer

Abstract

Background

Methods

Result

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Result

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Rare complication after thyroidectomy-cervical esophageal stenosis: a case report and literature review

Perineal approach for a gastrointestinal stromal tumor on the anterior wall of the lower rectum

Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma

Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment

Bilateral anterior sternothoracotomy (clamshell incision): a suitable alternative for bilateral lung sarcoma metastasis in children

Bile duct adenoma: a case report and literature review